Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.

被引：0
|
作者：
Cao, Guochun
Li, Xiaoyou
Liu, Delin
Zhu, Jinghua
机构：
[1] Nanjing Med Univ, Affiliated Canc Hosp, Dept Clin Oncol, Jiangsu Canc Hosp,Jiangsu Inst Canc Res, Nanjing, Peoples R China
[2] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Peoples R China
[3] China Jinagsu Prov Inst Canc Res, Nanjing, Jiangsu, Peoples R China
[4] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16022
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
    Chang, J.
    Wang, H.
    Hu, Z.
    Wang, J.
    Wu, X.
    Zhao, X.
    Sun, S.
    Yu, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1292 - S1292
  • [32] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [33] Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis
    Zhang, Xiaodong
    Lu, Ming
    Gong, Jifang
    Gao, Jing
    Wang, Xicheng
    Zhang, Xiaotian
    Li, Jie
    Li, Yan
    Li, Jian
    Zhou, Jun
    Lu, Zhihao
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Phase II clinical study of sorafenib combined with tislelizumab in the treatment of first-line unresectable hepatocellular carcinoma and the predictive effect and correlation of CTC
    Xu, L.
    Che, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S596 - S596
  • [35] First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis
    Zheng, Zhiwei
    Chen, Hongcai
    Cai, Hongfu
    Zhu, Huide
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (03) : 397 - 404
  • [36] TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase. trial
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Su-xia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Tislelizumab in Combination with Anlotinib as First-Line Treatment for Advanced Pulmonary Sarcomatoid Carcinoma: A Phase II Study
    Zeng, Z.
    Xiong, L.
    Zheng, Y.
    Zhang, X.
    Zhang, X.
    Liu, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S392 - S393
  • [38] A multicenter phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
    Kim, J.
    Song, H.
    Do, Y.
    Kim, M.
    Lee, K.
    Bae, S.
    Ryoo, H.
    Park, K.
    Baek, J.
    Lee, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab plus paclitaxel and cisplatin (TP) versus placebo plus TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma
    Shen, Lin
    Lu, Zhihao
    Xu, Linxinyu
    Wang, Yan
    Zhou, Hui
    Liu, Ying
    CANCER RESEARCH, 2019, 79 (13)
  • [40] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Lu, Shijie
    Lou, Yake
    Rong, Yi
    Huang, Zirui
    Lin, Xiaodan
    Chen, Junying
    Luo, Kongjia
    CLINICAL DRUG INVESTIGATION, 2023, 43 (08) : 643 - 652
12345